Key result
Ticagrelor is clinically superior to clopidogrel in acute coronary syndrome, resulting in significantly lower rates of myocardial infarction and vascular death.
Why the study?
Does ticagrelor reduce myocardial infarction and vascular death compared to clopidogrel in patients with acute coronary syndrome?
Population
Patients with an acute coronary syndrome
Comparison
Ticagrelor (administered with aspirin) vs Clopidogrel
Design
Review
Authors
Loading...
May support ticagrelor preference in ACS; leaves open need for contemporary outcome validation.
Does ticagrelor reduce myocardial infarction and vascular death compared to clopidogrel in patients with acute coronary syndrome?
Ticagrelor is an effective and reversible P2Y12 inhibitor that provides superior reduction in myocardial infarction and vascular death compared to clopidogrel in ACS patients, despite increased risks of specific bleeding events and dyspnea.
Nawarskas et al. (2011) conducted a review in Acute coronary syndrome. Ticagrelor vs. Clopidogrel was evaluated. Ticagrelor is clinically superior to clopidogrel in acute coronary syndrome, resulting in significantly lower rates of myocardial infarction and vascular death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: